Moderna Co-Founder Robert Langer Is A Billionaire Again As Shares Double In Value
Moderna rose 57% and Merck gained more than 6% after their personalized cancer vaccine showed positive late-stage trial results, analysts said.
- On Wednesday, Moderna and Merck announced positive results from a late-stage trial of an experimental mRNA vaccine to treat melanoma, a deadly skin cancer expected to claim more than 8,500 lives this year.
- The experimental mRNA vaccine, combined with Merck's immunotherapy drug Keytruda, proved effective at reducing recurrence risk in high-risk patients who underwent surgery.
- Professor Georgina Long, the study's principal investigator, described the findings as a 'landmark moment' for adjuvant melanoma treatment, noting the therapy aims to help patients remain cancer-free for longer.
- Shares of Moderna surged 145% to $154.48 on Wednesday, while Merck's stock jumped over 6%, boosting the personal net worth of company executives and co-founders.
- Drugmakers plan to present unpublished data at an upcoming international medical meeting, establishing a new treatment paradigm in the adjuvant melanoma setting.
13 Articles
13 Articles
A new strategy based on mRna technology opens up an interesting perspective in the fight against melanoma. An experimental vaccine developed by Moderna in collaboration with Merck has...
They announce positive preliminary results in the clinical trial of a melanoma vaccine, demonstrating a decrease in the recurrence of the disease and a dilatation in the development of metastases; Moderna rises by more than 150% Moderna and Merck pharmaceuticals are shooting on the Stock Exchange this Wednesday after announcing the achievement of positive preliminary results in the clinical trial of a melanoma vaccine, demonstrating a decrease i…
Moderna stock surges on claimed cancer vaccine breakthrough
Stock prices for the American vaccine manufacturer Moderna more than doubled on Wednesday after the company reported successful results from its messenger RNA melanoma cancer vaccine. The mRNA shot, in combination with Merck’s immunotherapy drug Keytruda, met critical benchmarks in a global late-stage clinical trial of more than 1,100 patients with higher-risk or advanced melanoma whose detectable cancer had been surgically removed. Merck’s st…
Phase 3 of its clinical trial has demonstrated decreased recurrence of the disease and dilation in the development of metastases
BT
avisendanmark.dkOn Wednesday, the American company Moderna announced positive results with a vaccine against melanoma.
Coverage Details
Bias Distribution
- 46% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
